Open Access

Prediction of acute kidney injury following coronary artery bypass graft surgery in elderly Chinese population



Wenxing Peng^{1*}, Bo Yang², Huanyu Qiao², Yongmin Liu² and Yang Lin¹

Abstract

Background Acute kidney injury (AKI) is a common and serious complication following coronary artery bypass graft (CABG) surgery. Advanced age is an independent risk factor for the development of AKI, and the incidence of AKI in the elderly increases more rapidly than that in younger patients. This study aimed to develop and validate the risk prediction model for AKI after CABG in elderly patients.

Methods Patients were retrospectively recruited from January 2019 to December 2020. AKI after CABG was defined according to the criteria of Kidney Disease Improving Global Outcomes (KDIGO). The entire population was divided into the derivation set and the verification set using random split sampling (ratio: 7:3). Lasso regression method was applied to screen for the variables in the derivation set. Decision curve analysis (DCA) and receiver operating characteristic (ROC) curves were plotted to analyze the predictive ability of the model for AKI risk in the derivation set and the verification set.

Results A total of 2155 patients were enrolled in this study. They were randomly divided into the derivation set (1509 cases) and the validation set (646 cases). Risk factors associated with AKI were selected by Lasso regression including T2DM, diabetes mellitus type intraoperative use of intra-aortic ballon pump (IABP), cardiopulmonary bypass (CPB), epinephrine, isoprenaline, and so on. The model was established by Lasso logistic regression. The area under the ROC curve (AUC) of the model for the derivation set was 0.754 (95% CI: 0.720 – 0.789), and that for the validation cohort was 0.718 (95% CI: 0.665 – 0.771).

Conclusion In this study, the model with significant preoperative and intraoperative variables showed good prediction performance for AKI following CABG in elderly patients to optimize postoperative treatment strategies and improve early prognosis.

Keywords Coronary artery bypass graft, Acute kidney injury, Model, Prediction

*Correspondence: Wenxing Peng shouyipwx@163.com ¹Department of Pharmacy, Beijing Anzhen Hospital, Capital Medical University, Beijing, China ²Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing, China



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Dublic Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Introduction

Along with advancements in medical technology, coronary artery bypass graft (CABG) surgery has become a common surgical treatment for patients with coronary heart disease (CHD) [1]. Acute kidney injury (AKI) is a common and serious complication of CABG surgery [2, 3]. It has been reported that the long-term mortality rate of patients with AKI is 11.8–29.8% [4, 5]. Furthermore, severe AKI is positively associated with higher morbidity and mortality, longer hospitalization duration, and increased medical costs [2].

The occurrence of AKI after CABG surgery is related to a series of factors, including demographic characteristics, age, sepsis, cardiac dysfunction, perioperative medication, and other perioperative factors [6, 7]. Among these, age appears to be one of the most relevant risk factors. Some studies have demonstrated that older age is an independent risk factor for the development of AKI [8, 9], and the incidence of AKI in the elderly increases more rapidly than that in younger patients [8]. The higher incidence and mortality of AKI in elderly patients (age \geq 65) was due to "kidney aging", a process of physiological, structural and functional involvement, which represents a further risk factor for AKI in elderly patients [10]. Thus, for elderly patients undergoing CABG, more attention should be paid to the prevention of AKI.

In postoperative AKI, elevated serum creatinine (SCr) levels appear relatively late after renal injury. Early identification of patients at high risk for AKI allows clinicians to monitor these patients in advance and take prophylaxis to prevent AKI. However, postoperative AKI cannot be predicted by a single risk factor or test. There are many variables related to the occurrence of AKI, and it is impossible to predict by the experience of a single clinician.

This retrospective study aimed to develop and validate the risk prediction model for AKI after CABG in elderly patients. We developed a risk prediction model using features from the preoperative, and intraoperative variables to identify high-risk elderly patients with AKI who were required to optimize the postoperative treatment strategy.

Methods

Study population

In this study, patients were retrospectively recruited from January 2019 to December 2020 according to the following inclusion criteria: (1) age>65 years, (2) patients who underwent CABG surgery without other concomitant procedures. Patients with the following conditions were excluded: (1) long-term preoperative dialysis, (2) renal transplantation recipients, (3) diagnosed with stage 4/5 chronic kidney disease (CKD) before surgery or baseline estimated glomerular filtration rate (eGFR)<30ml/min, (4) diagnosed with AKI before surgery, (5) died during surgery, (6) lack of baseline level of SCr, 5) lack of case data, (7) postoperative hospital stay>90 days.

Definition of postoperative AKI after CABG

According to Kidney Disease Improving Global Outcomes (KDIGO) criteria [11], postoperative AKI was defined as an increase of at least 50% within 7 days or 26.5 mmol/L elevation within 48 h after surgery compared with the baseline level of SCr. AKI stage 1 was defined as SCr of 1.5–1.9 times baseline or \geq 26.5µmol/L. AKI stage 2 was defined as SCr of 2.0-2.9 times baseline. AKI stage 3 was defined as SCr \geq 3.0 times baseline or SCr of \geq 353.6µmol/L or initiation of renal replacement therapy. Due to perioperative urine volume statistics were not detailed, urine volume was not included in the evaluation index of renal function. Urine output was not included in renal function assessment due to lack of detailed perioperative urine output. The baseline SCr was measured within seven days before surgery.

Statistical analysis

All statistical analyses were performed using R software 4.2.2. The entire population was divided into the derivation set and the verification set using random split sampling (ratio: 7:3). The Kolmogorov-Smirnov test was used to assess whether continuous data were normally distributed. Continuous data with normal distribution were presented as mean and standard deviation (SD) and analyzed using two-tailed Student's t-test. Continuous data with non-normal distribution were expressed as median and interquartile range (IQR) and analyzed using the Mann-Whitney U-test. Categorical data were expressed as counts and percentages and were analyzed using the Chi-squared or Fisher's exact test. Categorical data were expressed as counts and percentages and were analyzed using the Pearson chi-squared or two-sided Fisher's exact test. Statistical significance was set at P<0.05. Variables with more than 20% missing values were removed from further analysis. Others were inputted as the average values or modes for the variables. In the multivariable analysis of the derivation set, all variables that were predictors of AKI were included in the logistic regression model. Lasso regression method was applied to screen for the variables. The "glmnet" package was used to fit the logistic Lasso regression. AKI event was included in the logistic lasso regression as the dependent variable Y, coded 0 represents patients with AKI, 1 represents patients without AKI. Ten-fold cross-validation was used to select the penalty term lambda (λ). Binomial deviation was used to measure the prediction performance of the fitting model. The built-in function in R produces two automatic lambda values, and we chose lambda.min (λ with the minimal binomial deviation). DCA curve and confusion matrix were used for model evaluation Receiver operating characteristic (ROC) curves were plotted to analyze the predictive ability of the logistic Lasso regression model for AKI risk in the derivation set and the verification set, respectively. The area under the ROC curve (AUC) was used to evaluate the discrimination degree of the model. The calibration curve was used to evaluate the calibration degree of the model using 1000 times bootstrap samplings.

Results

Patient characteristics

A total of 2155 patients were enrolled in the study. Patients with AKI stage 1, stage 2 and stage 3 were 294

cases (13.6%), 52 cases (2.4%) and 19 cases (0.9%), respectively. They were randomly divided into the derivation set (1509 cases) and the validation set (646 cases). The cohort selection process used in this study was shown in Fig. 1. Baseline demographic and clinical characteristics of patients in the derivation set and the validation set were presented in Supplement Table 1. In the derivation set, 251 cases (16.6%) were assigned to the AKI group and 1258 cases (83.4%) to the non-AKI group according to the definition of postoperative AKI. In the original cohort, the median age was 69.2 years (range, 65.1–87.5 years), and 69.1% were male. The most common comorbidity was hypertension (65.4%), followed by hyperlipidemia (55.1%) and diabetes mellitus type 2



Fig. 1 Flowchart of cohort selection

(T2DM) (37.6%). There were no significant differences in sex, hypertension, hyperlipemia, prior cerebral infarction, prior PCI, lipid levels, etc. between the two groups (P>0.05). Patients in the AKI group were older than those in the non-AKI group (70.1 vs. 69.1 years, P=0.001). Additionally, patients in the AKI group had a higher New York Heart Association (NYHA) cardiac functional class (P<0.001) and a higher baseline level of B-type natriuretic peptide (BNP) (P<0.001) and SCr (P<0.001). The differences in other variables between the two groups were shown in Table 1.

Lasso regression analysis

Figure 2; Table 2 show the coefficient of variables in Lasso regression. The results revealed that risk factors associated with AKI included T2DM, diabetes mellitus type intraoperative use of intra-aortic ballon pump (IABP), cardiopulmonary bypass (CPB), epinephrine, isoprenaline, and so on. Preoperative use of proton pump inhibitor (PPI) and metformin, intraoperative use of cephalosporin, high intraoperative urine output, etc. were protective factors for AKI.

Model validation and calibration

To verify the predictive ability of themodel for the risk of AKI, ROC curves were plotted. As shown in Fig. 3, AUC for the derivation set was 0.754 (95% CI: 0.720-0.789) (Fig. 3A), and that for the validation cohort was 0.718 (95% CI: 0.665-0.771) (Fig. 3B). Confusion matrix diagram in the derivation set and the validation set were shown in Table 3. Decision curve analysis (DCA) was plotted to evaluate the accuracy of the model (Fig. 4). The sensitivity of the model in the derivation set and the validation set were 67.3% and 71.1%, respectively. Specificity of the model in the derivation set and the validation set were 71.3% and 63.5%, respectively (Table 4). Calibration curves were plotted to assess the calibration degree of the model in the derivation set and validation set. As shown in Fig. 4, the results of the derivation set (Fig. 5A) and the validation set (Fig. 5B) showed that the actual prediction and the simulation prediction were basically the same, indicating good agreement between the prediction and the actual observation result of AKI. These results suggest that the model has good predictive performance.

Discussion

The mechanism of AKI following CABG is multifactorial, including endothelial dysfunction, microcirculatory dysfunction, formation of microvascular thrombi, tubular injury, and intrarenal inflammation, which can alter renal perfusion and lead to AKI. During surgery, low flow, low pressure, rapid temperature reduction, use of CPB, and vasopressors can lead to renal hypoperfusion. After CABG, systemic inflammatory processes are activated for several days, which inevitably leads to changes in microvascular function, which may lead to renal hypoperfusion and ischemia even in the absence of arterial hypotension [12].

Yue et al. conducted a retrospective study to explore risk factors for AKI after CABG in 541 patients [13]. The analysis suggested that age, BMI, hypertension, eGFR, CPB time and postoperative low cardiac output syndrome were independent risk factors. Palomba et al. developed AKICS score to predict AKI following cardiac surgery, including age greater than 65 years, preoperative>1.2 mg/dl, preoperative capillary glucose>140 mg/ dl, heart failure, combined surgeries, cardiopulmonary bypass time>2 h, low cardiac output, and low central venous pressure [14]. Li et al. reported that age \geq 70 years, BMI \geq 25 kg/m², eGFR \leq 60 mL/min per 1.73 m2, ejection fraction \leq 45%, use of statins, red blood cell transfusion, use of adrenaline, IABP, postoperative low cardiac output syndrome and reoperation for bleeding were independent predictors of AKI [15]. The risk factors observed in previous studies were not entirely consistent with our findings. This study focused on elderly patients undergoing CABG, and the related risk factors might vary with age.

Different definitions of the elderly and the lack of consistent standards for identification of AKI might lead to discrepant research results. The recommendations of KDIGO for AKI are based on an exhaustive evidencebased review of the literature and provide guidance on clinical practice. According to the KDIGO criteria, the incidence of AKI after CABG was approximately 16.9% in this study. Yue et al. reported that the incidence of postoperative AKI following CABG was 27.9% [16] and Li et al. reported 37.5% [17], which was higher than that in our study. The possible reason was that our study had a stricter definition of the baseline SCr (baseline SCr was defined as the level of SCr within the 7 days before surgery, and all changes were compared with this baseline). And some AKI cases might be missed due to lack of perioperative urine output assessment. Another reason is that off-pump CABG is most common in our center, and the utilization rate of CPB is lower (only 16%), which causes less damage to the kidney.

T2DM has been reported as an independent risk factor for AKI after cardiac surgery [18]. Diabetic patients even with seemingly normal renal function have ultrastructural changes in kidney and malfunctional renal hemodynamics, reducing the ability to repair the injury [19]. A large retrospective cohort study revealed that participants with T2DM, were five times more likely to develop AKI than those without T2DM [20]. Possible mechanisms in patients with T2DM may be

Table 1 Baseline demographic and clinical characteristics of patients in the derivation set

NameNameNameNameAge iyears''602 (63)601 (63)602 (63)601 (63)602 (63)601 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)602 (63)<		Total	Non-AKI group	AKI group	P-value	
Demographicsset with a set of the set of		N=1509	N = 1258	N=251		
App (symath"602 (k0)603 (k0)603 (k0)003 (k1)003	Demographics					
Males on, (1%) 107. (67.0) 107. (67.0) 0.334 Dinker, n (%) 287. (07.0) 147. (07.0) 0.334 Dinker, n (%) 297. (07.0) 147. (07.0) 0.344 Dinker, n (%) 297. (07.0) 147. (07.0) 0.344 Complication, n (%) 257. (07.0) 147. (07.0) 0.05 Hypertraikin 197. (07.0) 126. (07.0) 126. (07.0) 0.05 Prior Mil 105. (00.0) 126. (07.0) 0.05 0.05 0.05 Prior Mil 105. (00.0) 126. (07.0) 0.16 0.05 0.05 0.05 Prior Crebbash infarction 105. (00.0) 124. (07.0) 0.06 0.06 Prior Crebbash infarction 105. (00.0) 124. (07.0) 0.06 0.06 Cocks HV 205. (05.0) 2.0 (10.0) 0.06 0.00 Dirac crebbash infarction 124. (07.0) 0.06 0.00 Dirac crebbash infarction 130. (07.0) 0.06 0.00 Cocks HV 205. (07.0) 0.01 0.00 <td< td=""><td>Age (years)*</td><td>69.2 (6.0)</td><td>69.1 (6.0)</td><td>69.9 (6.4)</td><td>0.017</td></td<>	Age (years)*	69.2 (6.0)	69.1 (6.0)	69.9 (6.4)	0.017	
Small Dmixen (%)294 (200)244 (200)244 (200)244 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)240 (200)24	Male sex, n (%)	1043 (69.1)	876 (69.6)	167 (66.5)	0.332	
Drinks Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bodymassinations Bod	Smoker, n (%)	298 (19.7)	254 (20.2)	44 (17.5)	0.334	
Body mask index (kg/m2)*252 (4.1)252 (4.1)24.9 (4.3)0.496Complication, n(%)Higher (19.00)10.10110.10210.10310.10110.10210.101HyperifermiaB31 (5.1)705 (56.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)12.6 (0.0)1	Drinker, n (%)	242 (16.0)	199 (15.8)	43 (17.1)	0.605	
Complexion (%)For (%)813 (%)813 (%)717 (%)0.000Hypertension567 (32.6)813 (%)121 (%2.0)0.000Hypertension567 (32.6)124 (%2.0)0.000Hypertension210 (%2.1)78 (%1.0)31 (%2.0)0.000Prior MC150 (%0.9)178 (%1.0)31 (%2.0)0.000Prior Action Creebal inferction160 (%0.9)160 (%0.9)100 (%0.9)0.000Prior Action Creebal inferction160 (%0.9)160 (%0.9)0.0000.000Prior Action Creebal inferction160 (%0.9)160 (%0.9)0.0000.000Prior Action Creebal inferction160 (%0.9)160 (%0.9)0.0000.000Chastillow160 (%0.9)160 (%0.9)0.0000.0000.000Prior Action Creebal inferction160 (%0.9)160 (%0.9)0.0000.0000.000Chastillow Creebal inferction160 (%0.9)76 (%0.9)77 (%0.9)0.0000.000Chastillow Creebal inferction160 (%0.9)76 (%0.9)77 (%0.9)0.0000.0000.0000.0000.0000.0000.0000.0000.0000.0000.0000.0000.0000.0000.0000.0000.0000.0000.0000.0000.0000.0000.0000.0000.0000.0000.0000.0000.0000.0000.0000.0000.0000.0000.0000.0000.0000.0000.0000.0000.0000.0000.0000.0000.00	Body mass index (kg/m2) *	25.2 (4.1)	25.2 (4.0)	24.9 (4.3)	0.469	
Hyperformation97 (65.4)81 (65.4)17.4 (0.3)0.131TZDM567 (75.6)146 (05.5)121 (46.0)0.000Hyperfiperina831 (55.1)70.5 (50.0)124 (0.0.3)0.000Prior cerebal infraction166 (10.9)134 (10.1)21 (20.4)0.030Prior Celebal infraction166 (10.9)134 (10.1)21 (20.4)0.030Prior Celebal infraction166 (10.9)134 (10.1)21 (20.4)0.030Prior CABG20 (10.1)163 (10.8)10.01134 (10.7)0.000WHA cardiac functional class, n(H)20 (10.1)0.0400.0010.0010.001VHA infract functional class, n(H)70 (10.1)0.0400.0010.0010.001Systolc blood pressure (mmHg)70 (10.2)70 (10.1)0.0400.0010.0010.001Systolc blood pressure (mmHg)70 (10.2)71 (10.1)0.0400.0010.0010.0010.001Systolc blood pressure (mmHg)70 (10.2)71 (10.1)0.0100.0010.0010.0010.0010.001Systolc blood pressure (mmHg)71 (10.1)0.0100.0110.0010.0010.0010.0010.001Systolc blood pressure (mmHg)71 (10.1)0.0110.0110.0110.0110.0110.0110.0110.011Systolc blood pressure (mmHg)71 (10.1)0.0110.0110.0110.0110.0110.0110.0110.0110.0110.0110.0110.0110.011 <td>Complication, n (%)</td> <td></td> <td></td> <td></td> <td></td>	Complication, n (%)					
TDM567 (27)446 (55)12 (42)0.001Hyperlipernia831 (51)778 (56)126 (50.2)0.089Pinor MI129 (14)178 (14)116.3)0.309Pinor CM165 (109)131 (124)0.300Pinor CABG29 (19)18 (14)11 (14)0.002WTH29 (19)18 (14)11 (14)0.002WTH29 (19)18 (14)11 (14)0.002Class II/W29 (19)18 (14)13 (18)0.010Diasto data76 (12)76 (12)71 (10)0.065Systolic blood pressure (mmHg)130 (17)130 (18)130 (18)0.010Diasto data96 (12)76 (12)76 (12)75 (29)0.024Mean artenia pressure (mmHg)97 (12)74 (21)72 (11)0.84 (12)0.024Diasto data74 (12)72 (12)75 (29)0.0010.024Diasto data74 (12)72 (12)75 (29)0.0010.024Diasto data74 (12)72 (12)75 (29)0.0010.024Diasto data74 (12)74 (12)74 (12)0.0110.024Diasto data74 (12)74 (12)74 (12)0.0240.024Diasto data74 (12)74 (12)74 (12)0.0110.024Diasto data74 (12)74 (12)74 (12)0.0240.024Diasto data74 (12)74 (12)74 (12)0.0240.024Diasto data74 (12)74 (12)74 (12)	Hypertension	987 (65.4)	813 (64.6)	174 (69.3)	0.153	
Hyperinemia831 (S1)75 (S0)12 (S0)0.26 (S0)Pior creboli infaction15 (100)134 (10.2)31 (12.4)0.36Pior Creboli infaction15 (100)134 (10.2)31 (12.4)0.30Pior CRG29 (1.9)12 (10.0)134 (10.2)31 (12.4)0.30Pior CRG29 (1.9)28 (1.0)12 (1.0)0.300.30WHA cardia functional class, n (%)29 (1.9)28 (1.0)69 (2.7)0.00WHA signs admission*76 (12)76 (12)77 (10)0.66Systolic blood pressure (mmHg)76 (12)76 (12)76 (12)76 (13)0.01Distolic blood pressure (mmHg)76 (12)94 / (12.0)94 / (12.0)95 (12.3)0.249Laboracy examinations at admission*77 4 (2.8)74 (2.10)72 (2.9)0.001Cir (uno/L)74 (2.10)74 (2.10)72 (2.10)72 (2.9)0.001Distolic blood pressure (mmHg)74 (12.0)74 (12.0)94 (12.0)94 (12.0)94 (12.0)94 (12.0)Cir (uno/L)74 (12.0)74 (12.0)74 (12.0)72 (12.0)72 (12.0)72 (12.0)72 (12.0)72 (12.0)72 (12.0)72 (12.0)72 (12.0)72 (12.0)72 (12.0)72 (12.0)72 (12.0)72 (12.0)72 (12.0)72 (12.0)72 (12.0)72 (12.0)72 (12.0)72 (12.0)72 (12.0)72 (12.0)72 (12.0)72 (12.0)72 (12.0)72 (12.0)72 (12.0)72 (12.0)72 (12.0)72 (12.0)72 (12.0)72 (12.0)72 (12.	T2DM	567 (37.6)	446 (35.5)	121 (48.2)	< 0.001	
Pior MI219 (45)74 (1.6)0.369Pior ceebral infarction165 (1.09)74 (1.0)21 (1.2)0.369Pior CABG165 (1.08)140 (1.1)23 (9.2)0.360Pior CABG20 (1.9)18 (1.4)11 (4.4)0.000VHA cardia functional class, n(%)25 (1.5)25 (1.8)69 (2.7)0.001VHA scription29 (1.9)28 (1.9)71 (1.0)0.065Systolic blood pressure (mmHg)130 (1.7)130 (1.8)130 (1.8)0.102Diaxolic blood pressure (mmHg)74 (2.9)74 (2.9)74 (2.9)8.2 (2.9)Diaxolic blood pressure (mmHg)74 (2.9)74 (2.9)74 (2.9)8.2 (2.9)Corret y examination s at admission"19.718.4 (2.3)74 (3.1)0.001GG (unol/L)19.771 (2.9)10.01110.0110.01110.0110.001Diaxolic blood pressure (mmHg)74 (1.9)72 (2.1)72 (2.9)72 (2.9)72 (2.9)72 (2.9)72 (2.9)72 (2.9)72 (2.9)72 (2.9)72 (2.9)72 (2.9)72 (2.9)72 (2.9)72 (2.9)72 (2.9)72 (2.9)72 (2.9)72 (2.9)72 (2.9)72 (2.9)72 (2.9)72 (2.9)72 (2.9)72 (2.9)72 (2.9)72 (2.9)72 (2.9)72 (2.9)72 (2.9)72 (2.9)72 (2.9)72 (2.9)72 (2.9)72 (2.9)72 (2.9)72 (2.9)72 (2.9)72 (2.9)72 (2.9)72 (2.9)72 (2.9)72 (2.9)72 (2.9)72 (2.9)72 (2.9)72 (2.9)<	Hyperlipemia	831 (55.1)	705 (56.0)	126 (50.2)	0.089	
Prior ceebral infarction165 (100)134 (10.7)31 (2.4)0.313Prior CABC16 (101)12 (302)0.300NPirer CABC11 (4.4)0.000NPTAcritia functional class, n (%)11 (4.4)0.000Vital signes at admission*1000100010001000Vital signes at admission*100010001000100010001000Systolic blood pressure (mmHg)100110010100101001010010100101001010010100101001010010100101001010010100101001010010100101001010010100101001010010100101001010010100101001010010100101001010010100101001010010100101001010010100101001010010100101001010010100101001010010100101001010010100101001010010100101001010010100101001010010100101001010010100101001010010100101001010010100101001010010100101001010010100101001010010100101001010010100101001010010100101001010010100101001010010100101001010010100101001010010100101001010010100101001010010100101001010	Prior MI	219 (14.5)	178 (14.1)	41 (16.3)	0.369	
Prior PCI163 (100)140 (11.1)23 (9.2)0.360Prior CABG20 (19)161 (14)10.000VHA cardia functional class, n (%)25 (19.5)26 (18.0)69 (27.5)0.001Class IU/V255 (19.5)256 (18.0)69 (27.5)0.001Vial sign at admission*76 (12)76 (12)76 (12)76 (10)0.652Systolic blood pressue (mmHg)76 (12)94 (12.0)95 (12.0)0.2020.202Distolic blood pressue (mmHg)77 (10)94 (12.0)95 (12.0)0.2020.202Cost operative acaminations at admission*77 (12.0)94 (12.0)95 (12.0)0.202GGFR (mL/min)77 (12.0)94 (12.0)75 (12.94)0.001CG (mm/l/l)72 (12.0)75 (12.94)0.0010.202UA (umol/L)71 (12.0)71 (12.0)71 (12.0)0.002UA (umol/L)21.0021.0021.000.002UA (umol/L)21.0021.0021.000.002UA (umol/L)21.0021.0021.000.002UA (umol/L)21.0021.0021.000.002UA (umol/L)21.0021.0021.0021.00UA (umol/L)21.0021.0021.0021.00UA (umol/L)21.0021.0021.0021.00UA (umol/L)21.0021.0021.0021.00UA (umol/L)21.0021.0021.0021.00UA (ul/L)21.0021.0021.0021.00UA	Prior cerebral infarction	165 (10.9)	134 (10.7)	31 (12.4)	0.431	
Prior CAGG29(1.9)18 (1.4)1.0.4.0)00000NTHA carlia functional class, n(%)295(1.8)295(1.8)6.0.7.0.50.0.0.0.0Class III/V295(1.8)295(1.8)0.0.0.0.00.0.0.0.0Mater and mission*76(1.2)76(1.0)1.0.0.0.0.0.0Distribution dipressure (mmHg)6.0.0.0.00.0.0.0.00.0.0.0.0Distribution dipressure (mmHg)6.0.0.0.00.0.0.0.00.0.0.0.0Distribution dipressure (mmHg)74(1.0)75(1.0)0.0.0.0Calcoret are commission*74(2.0)74(2.0)75(1.0)0.0.0.0SCr (umal/1)75(2.0)75(2.0)1.0.0.0.01.0.0.0.0SCr (umal/1)124(1.0)75(1.0)1.0.0.0.01.0.0.0.0L/A (umal/1)124(1.0)75(1.0)1.0.0.0.01.0.0.0.0Distribution distribution di	Prior PCI	163 (10.8)	140 (11.1)	23 (9.2)	0.360	
NPH A cardiac functional class, n (%) 261(a) 6 (a) 6 (a) Class II/V 261(b) 6 (a) 6 (a) 6 (a) Hair rate (bpm) 76 (12) 76 (12) 76 (10) 6 (a) Diastolic blood pressure (mmHg) 100 (1) 100 (1) 6 (a) Diastolic blood pressure (mmHg) 947 (12) 947 (12) 93 (12) 0 (2) EdFE (m/m)^ 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 74 (28) 7	Prior CABG	29 (1.9)	18 (1.4)	11 (4.4)	0.002	
Class II/IV 295 (19.5) 226 (18.0) 69 (27.5) 0.001 Vital sigs at admission* - - - - Heart rate (bpm) 76 (12) 76 (12) 76 (12) 76 (11) 0.684 Mean arterial pressure (mmHg) 76 (12) 76 (11) 76 (11) 0.684 Mean arterial pressure (mmHg) 76 (12) 76 (12) 75 (10) 0.684 Mean arterial pressure (mmHg) 77 (28,1) 78.4 (27.3) 71.4 (30.1) <0.001	NYHA cardiac functional class, n (%)					
Vital signs at admission* 76 (12) 77 (10) 0.065 Hear trate (bpm) 76 (12) 76 (12) 76 (11) 0.681 Systolic blood pressure (mmHg) 130 (17) 130 (17) 130 (17) 130 (17) 130 (17) 0.065 Diastolic blood pressure (mmHg) 94 / (120) 94 / (120) 94 / (120) 95 (123) 0.249 Laboratory examination at admission* E E F (11) 0.681 GCR (mL/min) 72 (21) 75 / (24) 0.001 (1240) 714 (20.1) <0.001	Class III/IV	295 (19.5)	226 (18.0)	69 (27.5)	0.001	
Hear rate (bpm) 76 (12) 76 (12) 77 (10) 0.065 Systilic blood pressure (mmHg) 130 (12) 130 (18) 0.012 Diastolic blood pressure (mmHg) 64 (12) 76 (12) 76 (12) 76 (10) 0.681 Mean atterial pressure (mmHg) 64 7 (120) 94 7 (120) 94 7 (120) 95 3 (12.3) 0.202 Laboratory examination s at admission* 77 (120) 75 7 (29.4) 0.001 CGF (mnL/Inin) 72.4 (21.9) 72.4 (21.9) 75 7 (29.4) 0.001 VA (µmol/L) 139.7 31.6 (12.40) 44.7 0.001 VA (µmol/L) 1880 174.0 (21.0) 26 26 26 PLT count (*10 ⁹ /L) 266.82 207 (82) 195 (70) 0.008 Low-density lipoprotein cholesterol (mmol/L) 1.38 (0.2) 1.30 (0.2) 0.302 Triglycerides (mm/L) 1.38 (0.2) 1.30 (0.2) 0.302 0.302 ALT (U/L) 1.30 (0.2) 1.30 (0.2) 1.30 (0.2) 0.302 0.302 ALT (U/L) 20 (16) <	Vital signs at admission*					
Systolic blood pressure (mmHg) 130 (17) 130 (18) 130 (18) 0.102 Diastolic blood pressure (mmHg) 76 (12) 76 (12) 76 (11) 0.684 Mean arterial pressure (mmHg) 76 (12) 76 (12) 76 (12) 75 (12) 75 (12) 0.001 Laboratory examination s at admission* 774 (28.1) 784 (27.3) 714 (30.1) <0.001	Heart rate (bpm)	76 (12)	76 (12)	77 (10)	0.065	
Diastolic blood pressue (mmHg) 76 (12) 76 (12) 76 (12) 76 (11) 0.684 Mean aterial pressure (mmHg) 94.7 (12.0) 94.7 (12.0) 95.3 (12.3) 0.249 Laboratory examination s at admission* eCFR (mL/min) 77.4 (28.1) 78.4 (27.3) 71.4 (30.1) <0.001	Systolic blood pressure (mmHa)	130 (17)	130 (18)	130 (18)	0.102	
Mean arterial pressure (mmHg) 94,7 (12,0) 94,7 (12,0) 95,3 (12,3) 0.249 Laboratory examinations at admission*	Diastolic blood pressure (mmHg)	76 (12)	76 (12)	76 (11)	0.684	
Laboratory examination s at admission* eCFR (mL/min) 77.4 (28.1) 78.4 (27.3) 71.4 (30.1) <0.001 SCr (µmol/L) 72.4 (21.9) 72 (21.1) 75.7 (29.4) 0.001 UA (µmol/L) 71.9 (21.1) 75.7 (29.4) 0.001 UA (µmol/L) 71.4 (21.0) 24.0 (21.0) 34.37 0.001 UA (µmol/L) 72.4 (21.9) 72.2 (21.1) 75.7 (29.4) 0.001 UA (µmol/L) 71.4 (0.21.0) 24.0 (0.01) (12.4.0) (12.4.0) (12.4.0) BNP (pg/ml) 128.0 17.4 (0.21.0) 25.1.0 <0.001	Mean arterial pressure (mmHg)	94.7 (12.0)	94.7 (12.0)	95.3 (12.3)	0.249	
eGFR (m/min) 77.4 (28.1) 78.4 (27.3) 71.4 (30.1) <0.001	Laboratory examination s at admission*		(,	,		
SCr (Linclus) Table of the second secon	eGER (ml /min)	77.4 (28.1)	78.4 (27.3)	71.4 (30.1)	< 0.001	
Luk (µmol/L) Table (1240) State (1)	SCr (umol/L)	72.4 (21.9)	72 (21)	75.7 (29.4)	0.001	
Instruction Instruction <thinstruction< th=""> <thinstruction< th=""></thinstruction<></thinstruction<>		319.7	3169(1240)	343.7	0.001	
BNP (pg/ml) 188.0 174.0 (21.3.0) 25.0. <0.001 PLT count (*10 ⁹ /L) 206 (82) 207 (82) 195 (79) 0.008 Low-density lipoprotein cholesterol (mmol/L) 2.33 (0.07) 2.33 (0.07) 2.33 (0.07) 0.807 Triglycerides (mmol/L) 1.48 (0.62) 1.49 (0.62) 4.47 (0.63) 0.957 Total cholesterol (mmol/L) 3.92 (0.97) 3.92 (0.98) 3.92 (0.9) 0.899 High-density lipoprotein cholesterol (mmol/L) 1.03 (0.25) 1.03 (0.24) 1.03 (0.29) 0.637 ALT (U/L) 1.91 (55) 20 (16) 17 (13) 0.014 AST (U/L) 1.91 (55) 356 (28.3) 59 (23.5) 0.12 AST (U/L) 1.91 (55) 356 (28.3) 59 (23.5) 0.12 AST (U/L) 1.91 (55) 356 (28.3) 59 (23.5) 0.12 AST (U/L) 2.92 (16) 17 (13) 0.017 Bet ablocker 155 (75.5) 389 (78.0) 166 (61.0) <0.001		(124.0)	51015 (12110)	(126.1)	0.001	
PLT count (*10 ⁹ /L) 206 (82) 207 (82) 195 (79) 0.008 Low-density lipoprotein cholesterol (mmol/L) 2.33 (0.70) 2.33 (0.70) 2.33 (0.70) 0.867 Triglycerides (mmol/L) 1.48 (0.62) 1.47 (0.63) 0.957 Total cholesterol (mmol/L) 3.92 (0.97) 3.92 (0.98) 3.92 (0.99) 0.899 High-density lipoprotein cholesterol (mmol/L) 1.03 (0.29) 1.03 (0.29) 0.637 ALT (U/L) 20 (16) 17 (13) 0.014 AST (U/L) 21 (11) 21 (12) 20 (16) 17 (13) 0.112 ASprin 415 (27.5) 356 (28.3) 59 (23.5) 0.12 Actin therapy 232 (15.4) 185 (14.7) 47 (18.7) 0.107 Beta blocker 1155 (76.5) 989 (78.6) 166 (6.1) <0.001	BNP (pg/ml)	188.0 (226.5)	174.0 (213.0)	251.0 (267.0)	<0.001	
Low-density lipoprotein cholesterol (mmol/L) 2.33 (0.79) 2.33 (0.70) 2.33 (0.70) 0.867 Triglycerides (mmol/L) 1.48 (0.62) 1.47 (0.63) 0.957 Total cholesterol (mmol/L) 3.92 (0.97) 3.92 (0.98) 3.92 (0.99) 0.899 High-density lipoprotein cholesterol (mmol/L) 1.03 (0.25) 1.03 (0.24) 1.03 (0.29) 0.637 ALT (U/L) 10(1) 21 (11) 21 (12) 0.014 AST (U/L) 20 (16) 17 (13) 0.014 AST (U/L) 21 (11) 21 (12) 0.016 AST (U/L) 21 (12) 23 (15.4) 185 (14.7) 47 (18.7) AST (U/L) 21 (12) 23 (15.4) 185 (14.7) 47 (18.7) 0.107 Beta blocker 1155 (76.5) 989 (78.6) 166 (66.1) <0.001	PLT count (*10 ⁹ /L)	206 (82)	207 (82)	195 (79)	0.008	
Triglycerides (mmol/L) 1.48 (0.62) 1.47 (0.63) 0.957 Total cholesterol (mmol/L) 3.92 (0.97) 3.92 (0.98) 3.92 (0.9) 0.899 High-density lipoprotein cholesterol (mmol/L) 1.03 (0.25) 1.03 (0.24) 1.03 (0.29) 0.637 ALT (U/L) 19 (15) 20 (16) 17 (13) 0.014 AST (U/L) 21 (11) 21 (12) 0.810 Preperative concomitant medication, n (%) 415 (27.5) 356 (28.3) 59 (23.5) 0.12 ACE inhibitor/ARB 232 (15.4) 185 (14.7) 47 (18.7) 0.107 Beta blocker 1155 (76.5) 989 (78.6) 166 (66.1) <0001	Low-density lipoprotein cholesterol (mmol/L)	2.33 (0.79)	2.33 (0.80)	2.33 (0.70)	0.867	
Total cholesterol (mmol/L) 3.92 (0.97) 3.92 (0.98) 3.92 (0.9) 0.899 High-density lipoprotein cholesterol (mmol/L) 1.03 (0.25) 1.03 (0.24) 1.03 (0.29) 0.637 ALT (U/L) 19 (15) 20 (16) 17 (13) 0.014 AST (U/L) 21 (11) 21 (11) 21 (12) 0.810 Preoperative concomitant medication, n (%) 115 (27.5) 356 (28.3) 59 (23.5) 0.12 AcE inhibitor/ARB 232 (15.4) 185 (14.7) 47 (18.7) 0.107 Beta blocker 1155 (76.5) 989 (78.6) 166 (66.1) <0.011	Triglycerides (mmol/L)	1.48 (0.62)	1.49 (0.62)	1.47 (0.63)	0.957	
High-density lipoprotein cholesterol (mmol/L) 1.03 (0.25) 1.03 (0.24) 1.03 (0.29) 0.637 ALT (U/L) 19 (15) 20 (16) 17 (13) 0.014 AST (U/L) 21 (11) 21 (11) 21 (12) 0.810 Preoperative concomitant medication, n (%) ACE inhibitor/ARB 232 (15.4) 185 (14.7) 47 (18.7) 0.107 Beta blocker 1155 (75.5) 989 (78.6) 166 (66.1) <0.001	Total cholesterol (mmol/L)	3.92 (0.97)	3.92 (0.98)	3.92 (0.9)	0.899	
ALT (U/L) 19 (15) 20 (16) 17 (13) 0.014 AST (U/L) 21 (11) 21 (11) 21 (12) 0.810 Preoperative concomitant medication, n (%) 415 (27.5) 356 (28.3) 59 (23.5) 0.12 AcE inhibitor/ARB 232 (15.4) 185 (14.7) 47 (18.7) 0.107 Beta blocker 1155 (76.5) 989 (78.6) 166 (66.1) <0.001	High-density lipoprotein cholesterol (mmol/L)	1.03 (0.25)	1.03 (0.24)	1.03 (0.29)	0.637	
AST (U/L) 21 (11) 21 (12) 21 (12) 0.810 Preoperative concomitant medication, n (%) 415 (27.5) 356 (28.3) 59 (23.5) 0.12 ASprin 415 (27.5) 356 (28.3) 59 (23.5) 0.12 ACE inhibitor/ARB 232 (15.4) 185 (14.7) 47 (18.7) 0.107 Beta blocker 1155 (76.5) 989 (78.6) 166 (66.1) <0001	ALT (U/L)	19 (15)	20 (16)	17 (13)	0.014	
Preoperative concomitant medication, n (%) It (1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1	AST (U/I)	21 (11)	21 (11)	21 (12)	0.810	
Aspirin415 (27.5)356 (28.3)59 (23.5)0.12ACE inhibitor/ARB232 (15.4)185 (14.7)47 (18.7)0.107Beta blocker1155 (76.5)989 (78.6)166 (66.1)<0.001	Preoperative concomitant medication, n (%)			· · /		
ACE inhibitor/ARB 232 (15.4) 185 (14.7) 47 (18.7) 0.107 Beta blocker 1155 (76.5) 989 (78.6) 166 (66.1) <0.001	Aspirin	415 (27.5)	356 (28.3)	59 (23.5)	0.12	
Beta blocker 1155 (76.5) 989 (78.6) 166 (66.1) <0.001 Statin therapy 288 (19.1) 249 (19.8) 39 (15.5) 0.117 PPI 370 (24.5) 326 (25.9) 44 (17.5) 0.005 Loop diuretic 304 (20.1) 233 (18.5) 71 (28.3) <0.001	ACE inhibitor/ARB	232 (15.4)	185 (14.7)	47 (18.7)	0.107	
Statin therapy 288 (19.1) 249 (19.8) 39 (15.5) 0.117 PPI 370 (24.5) 326 (25.9) 44 (17.5) 0.005 Loop diuretic 304 (20.1) 233 (18.5) 71 (28.3) <0.001	Beta blocker	1155 (76.5)	989 (78.6)	166 (66.1)	<0.001	
PPI 370 (24.5) 326 (25.9) 44 (17.5) 0.005 Loop diuretic 304 (20.1) 233 (18.5) 71 (28.3) <0.001	Statin therapy	288 (19.1)	249 (19.8)	39 (15.5)	0.117	
Loop diuretic 304 (20.1) 233 (18.5) 71 (28.3) <0.001	PPI	370 (24.5)	326 (25.9)	44 (17.5)	0.005	
Thiazide 54 (3.6) 45 (3.6) 9 (3.6) 0.995 Spirolactone 165 (10.9) 123 (9.8) 42 (16.7) 0.001 Contrast agent 385 (25.5) 318 (25.3) 67 (26.7) 0.639 Metformin 160 (10.6) 137 (10.9) 23 (9.2) 0.417 Intraoperative 885 (25.5) 318 (25.3) 67 (26.7) 0.601 PLT transfusion, n (%) 350 (23.2) 270 (21.5) 80 (31.9) <0.001	Loop diuretic	304 (20.1)	233 (18.5)	71 (28.3)	< 0.001	
Spirolactone 165 (10.9) 123 (9.8) 42 (16.7) 0.001 Contrast agent 385 (25.5) 318 (25.3) 67 (26.7) 0.639 Metformin 160 (10.6) 137 (10.9) 23 (9.2) 0.417 Intraoperative 885 (25.5) 318 (25.3) 67 (26.7) 0.639 PLT transfusion, n (%) 350 (23.2) 270 (21.5) 80 (31.9) <0.001	Thiazide	54 (3.6)	45 (3.6)	9(36)	0.995	
Contrast agent 105 (10.3) 112 (10.3) 112 (10.3) 100 (10.3) Metformin 385 (25.5) 318 (25.3) 67 (26.7) 0.639 Intraoperative 160 (10.6) 137 (10.9) 23 (9.2) 0.417 Intraoperative 350 (23.2) 270 (21.5) 80 (31.9) <0.001	Spirolactone	165 (10.9)	123 (9.8)	42 (16 7)	0.001	
Metformin 160 (10.6) 137 (10.9) 23 (9.2) 0.417 Intraoperative 350 (23.2) 270 (21.5) 80 (31.9) <0.001	Contrast agent	385 (25 5)	318 (25 3)	67 (26 7)	0.639	
Intraoperative 350 (23.2) 270 (21.5) 80 (31.9) <0.001	Metformin	160 (10.6)	137 (10.9)	23 (92)	0.035	
RBC transfusion, n (%) 350 (23.2) 270 (21.5) 80 (31.9) <0.001	Intraoperative	100 (10.0)	137 (10.5)	23 (3.2)	0.117	
PLT transfusion, n (%) 19 (1.3) 8 (0.6) 11 (4.4) <0.001	RBC transfusion n (%)	350 (23 2)	270 (21 5)	80 (31 9)	<0.001	
Plasma transfusion, n (%) 129 (8.5) 92 (7.3) 37 (14.7) <0.001 Use of IABP, n (%) 108 (7.2) 66 (5.2) 42 (16.7) <0.001	PLT transfusion n (%)	10 (1 2)	8 (0 6)	11 (4 4)	<0.001	
Use of IABP, n (%) 108 (7.2) 66 (5.2) 42 (16.7) <0.001	Plasma transfusion, n (%)	1 7 (1.3) 1 70 (2 5)	0 (0.0) 02 (7 3)	37 (17 7)		
100 (7.2) 00 (3.2) 42 (10.7) < 0.001	Ise of IARP n (%)	1 (L)	52 (7.3) 66 (5.2)	42 (16 7)		
		6 (0 A)	2 (∩ 2)	12(10.7)	0.001	

Table 1 (continued)

	Total	Non-AKI group	AKI group	P-value
	N=1509	N=1258	N=251	_
Use of CPB, n (%)	244 (16.2)	168 (13.4)	76 (30.3)	< 0.001
Use of epinephrine, n (%)	353 (23.4)	264 (21.0)	89 (35.5)	< 0.001
Use of norepinephrine, n (%)	841 (55.7)	703 (55.9)	138 (55.0)	0.793
Use of isoprenaline, n (%)	87 (5.8)	64 (5.1)	23 (9.2)	0.011
Use of dopamine, n (%)	1280 (84.8)	1070 (85.1)	210 (83.7)	0.575
Use of cephalosporin, n (%)	1235 (81.8)	1048 (83.3)	187 (74.5)	0.001
Operation time (h)*	4 (1)	4 (1)	4 (1)	0.099
Operation urine output (×100ml)*	12 (12)	12 (13)	10 (13)	0.003
Operation bleeding volume (×100ml)*	8 (4)	8 (4)	8 (4)	0.112
Operation total liquid intake (×100ml)*	25.0 (9.3)	25.0 (9.5)	24.0 (8.0)	0.002

Abbreviations: AKI, acute kidney injury; T2DM, diabetes mellitus type 2; MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; LVED, left ventricular end-diastolic diameter; eGFR, estimated glomerular filtration rate; SCr, serum creatinine; UA, uric acid; BNP, B-type natriuretic peptide; PLT, platelet; AST, aspartate amino transferase; ALT, alanine transaminase; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; PPI, proton pump inhibitor; RBC, red blood cell; IABP, intra-aortic ballon pump; ECMO, extracorporeal membrane oxygenation; CPB, cardiopulmonary bypass

Note: *Continuous data are expressed as median (interquartile range) and were calculated by Mann–Whitney U-test; Categorical data were presented as count (percentage) and were calculated by chi-squared test



Fig. 2 Plots for Lasso regression coefficients (A) and cross-validation plot for the penalty term (B)

generalized or intrarenal atherosclerosis, or tubular growth induced by chronic hyperglycemia may promote inflammation, senescence, and tubulointerstitial fibrosis, which enhance the susceptibility of diabetic kidneys to AKI [21, 22].

Cardiopulmonary bypass (CPB) is a form of extracorporeal circulation that temporarily replaces the function of the heart and lungs during surgery to maintain blood and oxygen circulation in patients. Studies have shown that 18.2 - 30% of patients undergoing cardiopulmonary bypass develop AKI, which is an important predictor of morbidity and mortality after cardiac surgery [23, 24]. Possible mechanisms included that hemeprotein-induced oxidative damage, free iron-mediated toxicity, excess oxidative stress, and endothelial dysfunction [25]. Saw et al. reported that longer CPB time and use of IABP were significantly associated with the development of AKI [26]. A possible reason was that use of IABP itself represents hemodynamic instability and might cause atheroemboli during surgery or bring additional hazards to the kidneys due to improper placement of the pump, blocking renal blood flow [27].

It is worth noting that preoperative and intraoperative medicines were also independent risk factors for AKI, which is easy to be neglected. Some medicines, such as preoperative PPI and metformin, exert protective effects on the kidney. Some studies have reported that metformin could significantly reduce renal inflammation, cellular infiltration and fibrosis, and protect kidneys from apoptosis, reactive oxygen stress and endoplasmic reticulum stress, which was independent of its hypoglycemic function [28, 29]. Though several studies have shown increase in SCr after cardiac surgery is associated with a significant increase in 30-day mortality [33]. Additionally, AKI after cardiac surgery may affect the long-term prognosis of patients and reduce their long-term survival rates. The risk of AKI in elderly patients could be reduced by identifying high-risk patients and adjusting risk factors in time.

Compared with previous studies, the differences in our study included the following: (1) This study mainly focused on elderly patients older than 65 years after CABG surgery, who are more prone to AKI due to weakened liver and kidney function and complex drug combination. Although there have been some previous studies on prediction systems for AKI after cardiac surgery, few focused on AKI after CABG surgery in elderly patients. (2) Considering that the United States, Canada, Singapore, Brazil and other countries have already developed warning systems for AKI after cardiac surgery. This study established a predictive model that was suitable for Chinese CABG patients. (3) We applied lasso regression to select variables that were more predictive of outcomes without increasing the risk of overfitting. The current study has several limitations. First, this was a single-center, retrospective study that only included single-center data. The effect of risk factors and performance of the model might differ from other centers with differently distributed population characteristics. Therefore, external validation is required. Second, only the available risk factors were included in this study. Some variables that were neglected or had many missing values were not included, which might affect the prediction performance of the model. Third, due to the unavailability of some variables and differences in study populations, we did not compare the performance of this model with previous risk models. And we did not perform subgroup analysis for different types of AKI due to the small number of AKI type2 and type3 cases. Lastly, the predictive ability was evaluated in the derivation set and the validation set using ROC curves. Future prospective studies are required to evaluate whether the application of the predictive model can reduce the risk of AKI in clinical practice.

Conclusions

This study aimed to develop and validate the risk prediction model for AKI after CABG in elderly patients. Variables were selected by lasso regression. The model showed a good prediction performance in the derivation set and validation set, which can help clinicians predict and reduce the occurrence of AKI after CABG surgery in elderly Chinese population.

 Table 2
 Variables and estimated coefficients by Lasso regression analysis

Variables	Coefficients
Constant	-0.167751
Age	0.001996
Hypertension	0.015928
T2DM	0.073192
Prior PCI	-0.001383
Prior CABG	0.090977
NYHA cardiac functional class III/IV	0.026491
Heart rate	0.000141
Systolic blood pressure	0.001253
eGFR	-0.000076
SCr	0.000661
UA	0.000029
BNP	0.000087
PLT	-0.000130
Triglycerides	-0.000923
ACE inhibitor/ARB	0.006850
Beta blocker	-0.034917
PPI	-0.031675
Loop diuretic	0.025012
Metformin	-0.034455
RBC transfusion	0.005728
PLT transfusion	0.159511
Plasma transfusion	0.001063
Use of IABP	0.149428
Use of ECMO	0.073207
Use of CPB	0.095614
Use of epinephrine	0.037103
Use of isoprenaline	0.053051
Use of dopamine	0.001977
Use of cephalosporin	-0.045134
Operation urine output	-0.002200
Operation total liquid intake	-0.000744

Abbreviations: AKI, acute kidney injury; T2DM, diabetes mellitus type 2; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; NYHA, New York Heart Association; eGFR, estimated glomerular filtration rate; SCr, serum creatinine; UA, uric acid; BNP, B-type natriuretic peptide; PLT, platelet; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; PPI, proton pump inhibitor; RBC, red blood cell; IABP, intra-aortic ballon pump; ECMO, extracorporeal membrane oxygenation; CPB, cardiopulmonary bypass

that PPI was associated with an increased risk of incident AKI [30, 31], which was contrary to our results. A possible reason for this was that perioperative use of PPI could prevent complications, such as stress ulcers, which reduced renal damage. Some medicines, such as epinephrine and isoprenaline, promoted the occurrence of AKI. The use of intraoperative vasoconstrictor drugs not only represented the patient's intraoperative hypotension but could also constrict renal vessels and reduce renal blood perfusion [31], which suggested that the use of vasoconstrictor drugs should be minimized during anesthesia.

In patients with AKI requiring dialysis after cardiac surgery, mortality is as high as 60–70% [32]. Even a slight



Fig. 3 Receiver operating characteristic (ROC) curves for the derivation set (A) and the validation set (B)

Table 3	Confusion	matrix	diagram	in the	derivation	set and the	
validatio	n set						

Data set	Values	Ac- tual value (positive)	Actual value (negative)
The derivation	Predict value (positive)	169	361
set	Predict value (negative)	82	897
The validation	Predict value (positive)	81	194
set	Predict value (negative)	33	338

Table 4	Validation value of the derivation set and the validation
set	

tivity	speci- ficity	INPV (%)		AC-
(%)	(%)	(70)	(%)	cu- racy (%)
67.3	71.3	91.6	31.9	70.6
71.1	63.5	91.1	29.5	64.9
	(%) 67.3 71.1	(%) (%) 67.3 71.3 71.1 63.5	(%) (%) 67.3 71.3 91.6 71.1 63.5 91.1	(%) (%) 67.3 71.3 91.6 31.9 71.1 63.5 91.1 29.5

Abbreviations: NPV, negative predictive value; PPV, positive predictive value



Fig. 4 Decision curve analysis of the model



Fig. 5 The calibration curves of the derivation set (A) and the verification set (B)

Abbreviations

ARB	Angiotensin receptor blocker
AST	Aspartate amino transferase
AUC	The area under the ROC curve
BNP	B-type natriuretic peptide
CABG	Coronary artery bypass graft
CCB	Calcium channel blocker
CI	Confidence interval
CPB	Cardiopulmonary bypass
ECMO	Extracorporeal membrane oxygenation
eGFR	Estimated glomerular filtration rate
IABP	Intra-aortic ballon pump
IQR	Interquartile range
KDIGO	Kidney Disease Improving Global Outcomes
LVED	Left ventricular end-diastolic diameter
LVEF	Left ventricular ejection fraction
MI	Myocardial infarction
NYHA	New York Heart Association
ORs	Odds ratios
PCI	percutaneous coronary intervention
PLT	platelet
PPI	proton pump inhibitor
RBC	red blood cell
ROC	receiver operating characteristic
SCr	serum creatinine
T2DM	diabetes mellitus type 2
UA	uric acid

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13019-023-02372-5.

Supplementary Material 1

Acknowledgements

We would like to thank Beijing Anzhen Hospital and all participants included in this study.

Authors' contributions

(I)Conception and design: WX-P. (II) Administrative support: YL and YM-L. (III) Determination of clinical events: WX-P and B-Y. (IV)Collection and uploading of

data: WX-P, B-Y, and YH-Q. (V) Data analysis and interpretation: B-Y, and YH-Q. (VI) Manuscript writing: WX-P and B-Y. (VII) Review and approval: All authors.

Data Availability

The dataset used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

This study protocol was approved by the Ethics Committee of Beijing Anzhen Hospital, Capital Medical University (No. 2021-069), and patient privacy was maintained throughout the study. All patients signed an informed consent form prior to recruitment.

Conflict of interest

The authors declare that they have no competing interests.

Competing interests

The authors declare no competing interests.

Received: 3 March 2023 / Accepted: 26 September 2023 Published online: 10 October 2023

References

- Beerkens FJ, Claessen BE, Mahan M, Gaudino MFL, Tam DY, Henriques JPS, Mehran R, Dangas GD. Contemporary coronary artery bypass graft surgery and subsequent percutaneous revascularization. Nat Rev Cardiol. 2022;19(3):195–208.
- Wang Y, Bellomo R. Cardiac surgery-associated acute kidney injury: risk factors, pathophysiology and treatment. Nat Rev Nephrol. 2017;13(11):697–711.
- Mariscalco G, Lorusso R, Dominici C, Renzulli A, Sala A. Acute kidney injury: a relevant complication after cardiac surgery. Ann Thorac Surg. 2011;92(4):1539–47.
- Rimes-Stigare C, Frumento P, Bottai M, Mårtensson J, Martling CR, Bell M. Long-term mortality and risk factors for development of end-stage renal disease in critically ill patients with and without chronic kidney disease. Crit Care. 2015;19:383.
- Rydén L, Sartipy U, Evans M, Holzmann MJ. Acute kidney injury after coronary artery bypass grafting and long-term risk of end-stage renal disease. Circulation. 2014;130(23):2005–11.

- Massoth C, Zarbock A, Meersch M. Acute kidney Injury in Cardiac surgery. Crit Care Clin. 2021;37(2):267–78.
- Amini S, Najafi MN, Karrari SP, Mashhadi ME, Mirzaei S, Tashnizi MA, Moeinipour AA, Hoseinikhah H, Aazami MH, Jafari M. Risk factors and outcome of Acute kidney Injury after isolated CABG surgery: a prospective cohort study. Braz J Cardiovasc Surg. 2019;34(1):70–5.
- Hsu RK, McCulloch CE, Dudley RA, Lo LJ, Hsu CY. Temporal changes in incidence of dialysis-requiring AKI. J Am Soc Nephrol. 2013;24(1):37–42.
- Koza Y. Acute kidney injury: current concepts and new insights. J Inj Violence Res. 2016;8(1):58–62.
- Infante B, Franzin R, Madio D, Calvaruso M, Maiorano A, Sangregorio F, Netti GS, Ranieri E, Gesualdo L, Castellano G, Stallone G. (2020) Molecular Mechanisms of AKI in the Elderly: from animal models to therapeutic intervention. J Clin Med 9(8).
- Thomas ME, Blaine C, Dawnay A, Devonald MA, Ftouh S, Laing C, Latchem S, Lewington A, Milford DV, Ostermann M. The definition of acute kidney injury and its use in practice. Kidney Int. 2015;87(1):62–73.
- Ostermann M, Liu K. Pathophysiology of AKI. Best Pract Res Clin Anaesthesiol. 2017;31(3):305–14.
- Yue Z, Yan-Meng G, Ji-Zhuang L. Prediction model for acute kidney injury after coronary artery bypass grafting: a retrospective study. Int Urol Nephrol. 2019;51(9):1605–11.
- Palomba H, de Castro I, Neto AL, Lage S, Yu L. Acute kidney injury prediction following elective cardiac surgery: AKICS score. Kidney Int. 2007;72(5):624–31.
- Li Y, Hou XJ, Liu TS, Xu SJ, Huang ZH, Yan PY, Xu XY, Dong R. Risk factors for acute kidney injury following coronary artery bypass graft surgery in a chinese population and development of a prediction model. J Geriatr Cardiol. 2021;18(9):711–9.
- Serraino GF, Provenzano M, Jiritano F, Michael A, Ielapi N, Mastroroberto P, Andreucci M, Serra R. Risk factors for acute kidney injury and mortality in high risk patients undergoing cardiac surgery. PLoS ONE. 2021;16(5):e0252209.
- Li Y, Xu J, Wang Y, Zhang Y, Jiang W, Shen B, Ding X. A novel machine learning algorithm, bayesian networks model, to predict the high-risk patients with cardiac surgery-associated acute kidney injury. Clin Cardiol. 2020;43(7):752–61.
- Mina GS, Gill P, Soliman D, Reddy P, Dominic P. Diabetes mellitus is associated with increased acute kidney injury and 1-year mortality after transcatheter aortic valve replacement: a meta-analysis. Clin Cardiol. 2017;40(9):726–31.
- Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: Challenges, Progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032–45.
- Hapca S, Siddiqui MK, Kwan RSY, Lim M, Matthew S, Doney ASF, Pearson ER, Palmer CNA, Bell S. The relationship between AKI and CKD in patients with type 2 diabetes: an Observational Cohort Study. J Am Soc Nephrol. 2021;32(1):138–50.

- 21. Akhtar M, Taha NM, Nauman A, Mujeeb IB, Al-Nabet A. Diabetic kidney disease: past and Present. Adv Anat Pathol. 2020;27(2):87–97.
- 22. Fu H, Liu S, Bastacky SI, Wang X, Tian XJ, Zhou D. Diabetic kidney diseases revisited: a new perspective for a new era. Mol Metab. 2019;30:250–63.
- Pickering JW, James MT, Palmer SC. Acute kidney injury and prognosis after cardiopulmonary bypass: a meta-analysis of cohort studies. Am J Kidney Dis. 2015;65(2):283–93.
- Haase M, Bellomo R, Story D, Letis A, Klemz K, Matalanis G, Seevanayagam S, Dragun D, Seeliger E, Mertens PR, Haase-Fielitz A. Effect of mean arterial pressure, haemoglobin and blood transfusion during cardiopulmonary bypass on post-operative acute kidney injury. Nephrol Dial Transplant. 2012;27(1):153–60.
- Liu D, Liu B, Liang Z, Yang Z, Ma F, Yang Y, Hu W. (2021) Acute Kidney Injury following Cardiopulmonary Bypass: A Challenging Picture. Oxid Med Cell Longev 2021:8873581.
- Saw KME, Ng RGR, Chan SP, Ang YH, Ti LK, Chew THS. Association of genetic polymorphisms with acute kidney injury after cardiac surgery in a southeast asian population. PLoS ONE. 2019;14(4):e0213997.
- Fan PC, Chen TH, Lee CC, Tsai TY, Chen YC, Chang CH. ADVANCIS score predicts acute kidney Injury after Percutaneous Coronary intervention for Acute Coronary Syndrome. Int J Med Sci. 2018;15(5):528–35.
- Corremans R, Vervaet BA, D'Haese PC, Neven E, Verhulst A. (2018) Metformin: a candidate drug for renal Diseases. Int J Mol Sci 20(1).
- 29. Song A, Zhang C, Meng X. Mechanism and application of metformin in kidney diseases: an update. Biomed Pharmacother. 2021;138:111454.
- Hart E, Dunn TE, Feuerstein S, Jacobs DM. Proton Pump inhibitors and risk of Acute and chronic kidney disease: a retrospective cohort study. Pharmacotherapy. 2019;39(4):443–53.
- Al-Aly Z, Maddukuri G, Xie Y. Proton Pump inhibitors and the kidney: implications of current evidence for clinical practice and when and how to Deprescribe. Am J Kidney Dis. 2020;75(4):497–507.
- 32. Rosner MH, Okusa MD. Acute kidney injury associated with cardiac surgery. Clin J Am Soc Nephrol. 2006;1(1):19–32.
- Lassnigg A, Schmidlin D, Mouhieddine M, Bachmann LM, Druml W, Bauer P, Hiesmayr M. Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: a prospective cohort study. J Am Soc Nephrol. 2004;15(6):1597–605.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.